Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Go back to Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD| (NASDAQ: OCUL) | Delayed: 9.97 +0.54 (5.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.43 | 52 Week High | $14.50 | |||
| Open | $9.51 | 52 Week Low | $4.04 | |||
| Day High | $10.14 | P/E | N/A | |||
| Day Low | $9.41 | EPS | $0.00 | |||
| Volume | 5,162,262 | |||||
